MICA and exocrine pancreatic carcinoma: Thus, out of six different epigenetic modifiers tested, only HDAC inhibitor VPA increased cell surface expression and/or release of MICA, MICB and ULBP-2 from the pancreatic carcinoma and prostate carcinoma cell lines irrespective of their allelic MICA variation.